Company profilePharmaceutical#684 of 1,318 in Pakistan✓ No DRAP alerts

NEXTAR PHARMA (PVT) LTD.

Pharmaceutical company · 15 brands · 11 molecules

Ranked #62 of 62 companies in Antivirals For Systemic Use

15 registered products 17 pharmaceutical brands 11 distinct molecules 0 DRAP alerts

Company overview

15
registered products
17
pharmaceutical brands
11
distinct molecules
3
therapeutic classes
0
DRAP alerts

NEXTAR PHARMA (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 15 product registrations across 11 distinct molecules. Its portfolio is concentrated in Antivirals For Systemic Use and Other Antianemic Preparations (Erythropoietin Products). It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by NEXTAR

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

3
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20263

Top molecules by brand count

Filgrastim2 brands
Enoxaparin Sodium ...... 60/1 brand
Erythropoietin ...... 2000 Iu1 brand
Erythropoietin ...... 4000 Iu1 brand
Erythropoietin ...... 10000 Iu1 brand
Peginterferon Alfa-2A1 brand

Therapeutic classes

Antivirals For Systemic Use · 1Other Antianemic Preparations (Erythropoietin Products) · 1Immunostimulants · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official12 products · Rs 1,100.21 – Rs 8,736.58
Median across source: Rs 3,125.18

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SAMI PHARMACEUTICALS (PVT) LTD. holds 170 molecules not in this portfolio
000 I.UAceclofenacAlprazolamAmikacinAmlodipineAnastrozole
SEARLE PAKISTAN (PVT.) LTD. holds 238 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for NEXTAR

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.